Reviewing Biocept (BIOC) and Lantheus Holdings (NASDAQ:LNTH)
Biocept (NASDAQ: BIOC) and Lantheus Holdings (NASDAQ:LNTH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitabiliy, analyst recommendations, valuation, risk and institutional ownership.
Institutional & Insider Ownership
15.3% of Biocept shares are held by institutional investors. Comparatively, 66.3% of Lantheus Holdings shares are held by institutional investors. 7.7% of Biocept shares are held by insiders. Comparatively, 2.3% of Lantheus Holdings shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Biocept has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500. Comparatively, Lantheus Holdings has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Biocept and Lantheus Holdings, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Biocept currently has a consensus price target of $2.50, indicating a potential upside of 78.57%. Lantheus Holdings has a consensus price target of $18.75, indicating a potential downside of 0.53%. Given Biocept’s stronger consensus rating and higher possible upside, analysts clearly believe Biocept is more favorable than Lantheus Holdings.
This table compares Biocept and Lantheus Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Biocept and Lantheus Holdings’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Biocept||$4.68 million||7.96||-$17.28 million||($1.65)||-0.85|
|Lantheus Holdings||$317.61 million||2.22||$75.23 million||$0.72||26.18|
Lantheus Holdings has higher revenue and earnings than Biocept. Biocept is trading at a lower price-to-earnings ratio than Lantheus Holdings, indicating that it is currently the more affordable of the two stocks.
Lantheus Holdings beats Biocept on 7 of the 13 factors compared between the two stocks.
Biocept Company Profile
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.
Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.